688197 首药控股
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-6.476-23.163-16.662-28.777-195.939
总资产报酬率 ROA (%)-5.679-20.836-15.391-25.610-123.473
投入资产回报率 ROIC (%)-6.417-23.029-16.570-28.483-191.191

边际利润分析
销售毛利率 (%)100.00098.95697.87199.37199.932
营业利润率 (%)-2,552.387-5,376.314-3,548.333-9,518.597-1,116.806
息税前利润/营业总收入 (%)-2,546.317-5,511.391-3,911.122-10,613.206-1,122.645
净利润/营业总收入 (%)-2,537.551-5,376.400-3,548.792-9,512.739-1,111.996

收益指标分析
经营活动净收益/利润总额(%)110.343106.795107.506114.578112.123
价值变动净收益/利润总额(%)-9.621-8.186-3.827-0.6550.000
营业外收支净额/利润总额(%)-0.5850.0020.013-0.062-0.433

偿债能力分析
流动比率 (X)6.9467.05410.89813.4950.687
速动比率 (X)6.9317.02410.89513.4690.659
资产负债率 (%)12.36212.2768.1977.13797.419
带息债务/全部投入资本 (%)0.7630.5730.2210.485-3.823
股东权益/带息债务 (%)12,987.99917,304.74145,149.97320,485.261-803.100
股东权益/负债合计 (%)708.922714.5811,119.9701,301.0842.650
利息保障倍数 (X)290.46740.82810.7949.644105.421

营运能力分析
应收账款周转天数 (天)44.8008.3210.000374.34352.484
存货周转天数 (天)--16,031.7384,113.77458,806.56685,920.599